Structure-activity relationships among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter

Journal of Neurochemistry

Volumn 74, Issue 6, 2000, Pages 2597-2606

  Jarrahian, Abbas ^a   Manna, Sukumar ^a,b   Edgemond, William S ^a   Campbell, William B ^a   Hillard, Cecilia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Cannabinoid receptor; Endocannabinoid; Fatty acid amide hydrolase; N Arachidonylethanolamine

Indexed keywords

AMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; ETHANOLAMINE DERIVATIVE;

ARTICLE; DIFFUSION; ENZYME ACTIVITY; GRANULE CELL; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; CANNABINOIDS; CARRIER PROTEINS; CELLS, CULTURED; CEREBELLUM; CYCLOHEXANOLS; ENDOCANNABINOIDS; GLYCERIDES; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; NEURONS; POLYUNSATURATED ALKAMIDES; PROSENCEPHALON; RATS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; TRITIUM;

EID: 0034070409     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0742597.x     Document Type: Article

References (39)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L. A., Pertwee R. G., and Makriyannis A. (1994) (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37, 1889-1893.
2. Beltramo M., di Tomaso E., and Piomelli D. (1997a) Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. FEBS Lett. 403, 263-267.
3. Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., and Piomelli D. (1997b) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097.
4. Bisogno T., Maurelli S., Melck D., De Petrocellis L., and Di Marzo V. (1997) Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 212, 3315-3323.
5. Bouaboula M., Bourrie B., Rinaldi-Carmona M., Shire D., Le Fur G., and Casellas P. (1995a) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J. Biol. Chem. 270, 13973-13980.
6. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. (1995b) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312, 637-641.
7. Calignano A., La Rana G., Beltramo M., Makriyannis A., and Piomelli D. (1997) Potentiation of anandamide hypotension by the transport inhibitor. AM404. Eur. J. Pharmacol. 337, R1-R2.
8. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3110.
9. Childers S., Sexton T., and Roy M. (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol. 47, 711-715.
10. Cravatt B., Prospero-Garcia O., Siuzdak G., Gilul N., Henriksen S., Bolger D., and Lerner R. (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268, 1506-1509.
11. Cravatt B., Giang D., Mayfield S., Bolger D., Lerner R., and Guila N. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature 384, 84-87.
12. Deutsch D. and Chin S. (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46, 791-796.
13. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
14. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J. C., and Piomelli D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
15. Di Marzo V., Bisogno T., Melck D., Ross R., Brockie H., Stevenson L., Pertwee R., and De Petrocellis L. (1998a) Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436, 449-454.
16. Di Marzo V., Bisogno T., Sugiura T., Melck D., and De Petrocellis L. (1998b) The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J. 331, 15-19.
17. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J. A., and Kunos G. (1999) Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264, 258-267.
18. Edgemond W. S., Campbell W. B., and Hillard C. J. (1995) The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids 52, 84-86.
19. Felder C., Briley E., Axelrod J., Simpson J., Mackie K., and Devane W. (1993) Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA 90, 7656-7660.
20. Goparaju S. K., Ueda N., Yamaguchi H., and Yamamoto S. (1998) Anandamide amidohydrolase reacting with 2-arachidonylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422, 69-73.
21. Hillard C. J. and Campbell W. B. (1997) Biochemistry and pharmacology of arachidonylethanolamine, a putative endogenous cannabinoid. J. Lipid Res. 38, 2383-2398.
22. Hillard C. J., Wilkison D. M., Edgemond W. S., and Campbell W. B. (1995a) Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim. Biophys. Acta 1257, 249-256.
23. Hillard C. J., Edgemond W. S., and Campbell W. B. (1995b) Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J. Neurochem. 64, 677-683.
24. Hillard C. J., Edgemond W. S., Jarrahian A., and Campbell W. B. (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69, 631-638.
25. Hillard C. J., Manna S., Greenberg M. J., DiCamelli R., Ross R. A., Stevenson L. A., Murphy V., Pertwee R. G., and Campbell W. B. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289, 1427-1433.
26. Howlett A. C., Mukhopadhyay S., Shim J. Y., and Welsh W. J. (1999) Signal transduction of eicosanoid CB1 receptor ligands. Life Sci. 65, 617-625.
27. Khanolkar A. D. and Makriyannis A. (1999) Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. Life Sci. 65, 607-616.
28. Khanolkar A. D., Abadji V., Lin S., Hill W. A. G., Taha G., Abouzid K., Meng Z., Fan P., and Makriyannis A. (1996) Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39, 4514-4519.
29. Lang W., Qin C., Lin S., Khanolkar A. D., Goutopoulos A., Fan P., Abouzid K., Meng Z., Biegel D., and Makriyannis A. (1999) Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J. Med. Chem. 42, 896-902.
30. Lin S., Khanolkar A. D., Fan P., Goutopoulos A., Qin C., Papahadjis D., and Makriyannis A. (1998) Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem. 41, 5353-5361.
31. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N. E., Schatz A. R., Gopher A., Almog S., Martin B. R., Compton D. R., Pertwee R. G., Griffin G., Bayewitch M., Barg J., and Vogel Z. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90.
32. Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., and Di Marzo V. (1999) Unsaturated long-chain N-acylvanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CBI cannabinoid receptors. Biochem. Biophys. Res. Commun. 262, 275-284.
33. Muthian S., Nithipatikom K., Campbell W. B., and Hillard C. J. (2000) Synthesis and characterization of a fluorescent substrate for the anandamide transmembrane carrier. J. Pharmacol. Exp. Ther. (in press).
34. Ng E. W., Aung M. M., Abood M. E., Martin B. R., and Razdan R. K. (1999) Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. J. Med. Chem. 42, 1975-1981.
35. 14C] as a substrate for anandamide amidase. Life Sci. 56, 2033-2040.
36. Piomelli D., Beltramo M., Glasnapp S., Lin S. Y., Goutopoulos A., Xie X. Q., and Makriyannis A. (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA 96, 5802-5807.
37. Schmid P. C., Zuzarte-Augustin M. L., and Schmid H. H. O. (1985) Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 260, 14145-14149.
38. Stella N., Schweitzer P., and Piomelli D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
39. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-92.